The (Tc(N)(PNP))2+ metal fragment labeled cholecystokinin-8 (CCK8) peptide for CCK-2 receptors imaging: In vitro and in vivo studies

Journal of Peptide Science

Volumn 13, Issue 4, 2007, Pages 211-219

  Agostini, Stefania ^a   Bolzati, Cristina ^a,b   Didonè, Eliana ^a   Cavazza Ceccato, Mario ^a   Refosco, Fiorenzo ^b   Aloj, Luigi ^c   Arra, Claudio ^c   Aurilio, Michela ^c   Tornesello, Anna Lucia ^d   Tesauro, Diego ^d   Morelli, Giancarlo ^d  

^a UNIVERSITY OF PADOVA   (Italy)

^b CNR   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

CCK8 peptide conjugate; Nuclear medicine; Tc nitrido complexes; Technetium

Indexed keywords

BUFFER; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ OCTAPEPTIDE; CYSTEINE; GLUTATHIONE; NICKEL; PHOSPHATE; RADIOISOTOPE; TECHNETIUM 99M;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS SOLUTION; ARTICLE; BINDING AFFINITY; BIOACCUMULATION; CHELATION; CHEMICAL PROCEDURES; CHEMICAL REACTION KINETICS; COMPLEX FORMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TEMPERATURE; INCUBATION TIME; INTERMETHOD COMPARISON; ISOTOPE LABELING; LIVER HOMOGENATE; MOLECULAR STABILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; PROVOCATION TEST; THERMODYNAMICS; TUMOR XENOGRAFT;

ANIMALS; BUFFERS; CHOLECYSTOKININ; HUMANS; ISOTOPE LABELING; MICE; MICE, NUDE; MOLECULAR BIOLOGY; ORGANOTECHNETIUM COMPOUNDS; PEPTIDE FRAGMENTS; RADIOPHARMACEUTICALS; RECEPTOR, CHOLECYSTOKININ B; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 34247348172     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.834     Document Type: Article

References (33)

1. Boerman OC, Oyen WJ, Corstens FH. Radio-labeled receptor-binding peptides: a new class of radiopharmaceuticals. Semin. Nucl. Med. 2000; 30: 195-208.
2. Reubi JC, Mäecke HR. Krenning EP. Candidate for peptide receptor radiotherapy today and in the future. J. Nucl. Med. 2005: 46: 67S-75S.
3. Weiner RE, Thakur ML. Radiolabeled peptides in diagnosis and therapy of oncological diseases. Appl. Radiat. Isot. 2002; 57: 749-763.
4. Fichna J, Janecka A. Synthesis of target specific radiolabeled peptides for diagnostic imaging. Bioconjugate Chem. 2003: 14: 3-17.
5. 99mTc labeling of highly potent small peptides. Bioconjugate Chem. 1997: 8: 621-636.
6. 99mTc-labeled small peptides as diagnostic radiopharmaceutical. Chem. Rev. 1999: 99: 2235-2268.
7. + (M = Re, Tc) directed towards radiopharmaceutical application. Coord Chem. Rev. 1999: 190-192: 901-919.
8. Bolzati C, Boschi A, Duatti A, Prakash S. Uccelli L, Refosco, F. Tisato F, Bandoll G. Geometrically controlled selective formation of nitrido technetium(V) asymmetrical heterocomplexes with bidentate ligands. J. Am. Chem. Soc. 2000: 122: 4510-4511.
9. 2+ (PXP = Diphosphine ligand). A novel tool for the selective labeling of small molecules. J. Am. Chem. Soc. 2002; 124: 11468-11479.
10. 2+ (PXP = Diphosphine ligand). Bioconjugate Chem. 2001; 12: 1035-1042.
11. 2+ metal fragment: a technetium-Nitrido Synthon for use with biologically active molecules. The N-(2-Methoxyphenyl)plpcrazyl-cysteine analogues as examples. Bioconjugate Chem. 2003: 14: 1231-1242.
12. Boschi A, Uccelli, Duatti A, Bolzati C. Refosco F, Tisato F, Romagnoli R., Baraldi PG, Varani K, Borea PA. Asymmetrical nitrido Tc-99m heterocomplexes as potential imaging agents for benzodiazepine receptors. Bioconjugate Chem. 2003; 14: 1279-1288.
13. 2+ metal fragment. J. Nucl. Med. Biol. 2007 (in press).
14. Bolzati C, Refosco F. Cagnolini A, Tisato F, Boschi A. Duatti A. Uccelli L, Dolmella A, Marotta E, Tubaro M. Synthesis, solution-state and solid-state structural characterization of monocationic nitrido heterocomplexes [M(N)(DTC)(PNP)i + (M = 99Tc, Re ∼ DTC = Dithiocarbammate; PNP = Heterodiphosphine). Eur. J. Inorg. Chem. 2004; 9: 1902-1913.
15. Bolzati C, Benini E, Cazzola E, Jung C, Tisato F. Refosco F, Pietzsch HJ, Spies H, Uccelli L, Duatti A. Synthesis, characterization and biological evaluation of neutral nitrido technetium(V) mixed ligand complexes containing dithiolates and aminodiphosphanes. A novel system for linking technetium to biomolecules. Bioconjugate Chem. 2004; 15: 628-637.
16. +. In Technetium. Rhenium and Other Metals in Chemistry and Nuclear Medicine 7, Mazzi U (ed.). Padova: Italy, 2006; 395-398.
17. Béhé M. Behr TM. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Biopolymers 2002; 66: 399-418.
18. Reubl JC, Waser B. Unexpected high incidence of cholecystokinin B/ gastrin receptors in human medullary thyroid carcinomas. Int. J. Cancer 1996; 67: 644-647.
19. Reubi JC, Schaer JC, Waser B. Cholecystokinin (CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res 1997; 57: 1377-1386.
20. lmdahl A, Mantamadiotis T. Eggstein S, Farthmarm EH, Baldwin GS. Expression of gastrin, gastrin/CCK-B and gastrin CCK-C receptors in human colorectal carcinomas. J. Cancer Res. Clin. Oncol. 1995; 121: 661-666.
21. Behr TM, Jenner N, Radetzky S, Béhe M. Gratz S. Yucekent S, Raue F. Becker W. Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabeled gastrin. Eur. J. Nucl. Med. 1998, 25: 424-430.
22. Reubi JC, Waser B. Schaer JC, Laederch U, Erion J, Srinivasan A. Schmidt MA. Bugaj JE. Unsulfated DTPA- and DOTA-CCK analogs as specific high-affinity ligands for CCK-13 receptor-expressing human and nat tissues in vitro and in vivo. Eur. J. Nucl. Med. 1998; 25: 481-490.
23. 111 in-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy. J. Nucl. Med. 1999; 40: 2081-2087.
24. Kwekkeboom DJ, Bakker WH, Kooij PPM, Erion J, Srinivasan A, de Jong M, Reubi JC, Krenning EP. Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma. Eur. J. Nucl. Med. 2000; 27: 1312-1317.
25. Behr TM, Jenner N, Béhé M, Angerstein C, Gratz S, Raue F, Becker W. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J. Nucl. Med. 1999; 40: 1029-1044.
26. Béhé M. Becker W. Gotthardt M, Angerstein C. Behr TM. Improved kinetic stability of DTPA-DGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labeled minigastrin derivatives. Eur. J. Nucl. Med. Mol. Imaging 2003: 30: 1140-1146.
27. 111 In-DTPAG]u-G-CCK8 for cholecystokinin-B receptor imaging. J. Nucl. Med. 2004; 45: 485-494.
28. Behr TM, Béhé M. Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin. Nucl. Med. 2002; 32: 97-109.
29. Laverman P, Béhé M, Oyen WJG, Willems PHGM, Corstens FHM. Behr TM, Boerman OC. Two technetium-99m-labeled cholecystokinin-8 (CCK8) peptides for scintigraphic imaging of CCK receptors. Bioconjugate Chem 2004; 15: 561-568.
30. 99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Nα-His)acetic acid-modified [D-Glul1]minigastrin. Bioconjugate Chem. 2004; 15: 864-871.
31. 99m-Tc-labeled minigastrin analogs. J. Nucl. Med. 2005; 46: 1727-1736.
32. Morelli G, De Luca S. Tesauro D. Saviano M. Pedone C, Dolmella. A, Visentin P. Mazzi U. CCK8 peptide derivatized with diphenylphosphine for rhenium labelling: synthesis, molecular mechanics and quantum mechanics calculations. J. Pept. Sci. 2002; 8: 373-381.
33. Behe M, Kluge G, Becker W. Gotthardt M, Behr TM. Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. J. Nucl. Med. 2005; 46: 1012-1015.